Intercept Pharmaceuticals Croissance future

Future contrôle des critères 4/6

Intercept Pharmaceuticals devrait augmenter ses bénéfices et son chiffre d'affaires de 42.4% et de 2.3% par an respectivement. Le BPA devrait croître de de 42.7% par an. Le rendement des capitaux propres devrait être 46.4% dans 3 ans.

Informations clés

42.4%

Taux de croissance des bénéfices

42.7%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.4%
Taux de croissance des recettes	2.3%
Rendement futur des capitaux propres	46.4%
Couverture par les analystes	Good
Dernière mise à jour	07 Nov 2023

Mises à jour récentes de la croissance future

Recent updates

Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive

Jun 08

Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Apr 11

Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Dec 20

Intercept touts Ocaliva benefit in transplant-free survival in liver disease type

Sep 20

Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

May 10

Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH

Mar 05

Intercept names Andrew Saik as chief financial officer

Jun 07

Intercept Pharmaceuticals slides as FDA restricts Ocaliva use

May 26

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:ICPT - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2025	362	98	150	177	13
12/31/2024	362	107	125	147	15
12/31/2023	331	-34	-15	-51	4
9/30/2023	318	-57	-63	-63	N/A
6/30/2023	306	-159	-96	-96	N/A
3/31/2023	295	-173	-59	-58	N/A
12/31/2022	286	-175	-27	-27	N/A
9/30/2022	277	-202	-18	-17	N/A
6/30/2022	266	-115	3	3	N/A
3/31/2022	263	-120	-7	-7	N/A
12/31/2021	261	-136	-41	-41	N/A
9/30/2021	275	-144	-65	-62	N/A
6/30/2021	288	-193	-110	-106	N/A
3/31/2021	297	-231	-130	-126	N/A
12/31/2020	234	-273	-176	-172	N/A
9/30/2020	301	-321	-217	-215	N/A
6/30/2020	283	-339	-222	-221	N/A
3/31/2020	272	-347	-253	-252	N/A
12/31/2019	252	-345	-238	-237	N/A
9/30/2019	234	-335	-230	-229	N/A
6/30/2019	219	-314	-235	-234	N/A
3/31/2019	196	-318	-236	-235	N/A
12/31/2018	180	-309	-241	-241	N/A
9/30/2018	164	-333	-265	-264	N/A
6/30/2018	159	-341	-271	-269	N/A
3/31/2018	146	-352	-283	-277	N/A
12/31/2017	131	-360	-276	-265	N/A
9/30/2017	107	-369	-290	-278	N/A
6/30/2017	71	-385	N/A	-334	N/A
3/31/2017	46	-376	N/A	-350	N/A
12/31/2016	25	-413	N/A	-342	N/A
9/30/2016	12	-381	N/A	-319	N/A
6/30/2016	7	-343	N/A	-240	N/A
3/31/2016	2	-314	N/A	-203	N/A
12/31/2015	3	-226	N/A	-163	N/A
9/30/2015	3	-173	N/A	-129	N/A
6/30/2015	3	-158	N/A	-120	N/A
3/31/2015	3	-77	N/A	-105	N/A
12/31/2014	2	-283	N/A	-88	N/A
9/30/2014	2	-261	N/A	-66	N/A
6/30/2014	2	-257	N/A	-49	N/A
3/31/2014	2	-304	N/A	-35	N/A
12/31/2013	2	-68	N/A	-28	N/A
9/30/2013	2	-86	N/A	-22	N/A
6/30/2013	2	-61	N/A	-19	N/A
3/31/2013	2	-53	N/A	-17	N/A
12/31/2012	2	-46	N/A	-16	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ICPT devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.2% ).

Bénéfices vs marché: ICPT devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: ICPT devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ICPT ( 2.3% par an) devrait croître plus lentement que le marché de US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ICPT ( 2.3% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de ICPT devrait être très élevé dans 3 ans ( 46.4 %).

Intercept Pharmaceuticals Croissance future

Future contrôle des critères 4/6

Informations clés

Mises à jour récentes de la croissance future

Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023

Price target decreased by 24% to US$15.08

Price target decreased by 14% to US$21.00

Forecast breakeven date moved forward to 2024

Consensus EPS estimates fall by 11%

Recent updates

Intercept Pharmaceuticals, Inc. Receives Complete Response Letter from FDA Addressing OCALIVA Supplemental New Drug Application (sNDA)

Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market

Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT).

Third quarter 2023 earnings: EPS exceeds analyst expectations

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT) for approximately $840 million.

Now 20% undervalued after recent price drop

Now 22% undervalued after recent price drop

Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Price target decreased by 24% to US$15.08

Intercept Pharmaceuticals, Inc. Presents New Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage

Intercept Pharmaceuticals, Inc. Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive

Price target decreased by 14% to US$21.00

Forecast breakeven date moved forward to 2024

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 11%

Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Price target increased by 9.9% to US$24.00

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 8.2% to US$20.85

U.S. Food and Drug Administration Accepts Intercept Pharmaceuticals, Inc.'s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to Nash

Consensus forecasts updated

Forecast breakeven date pushed back to 2025

Intercept Pharmaceuticals, Inc. Resubmits New Drug Application to U.S. Fda for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH

Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Consensus forecasts updated

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Intercept Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid in Compensated Cirrhosis Due to Nash Did Not Meet Its Primary Endpoint

Price target decreased to US$24.00

Intercept Pharmaceuticals, Inc. Announces Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

Intercept touts Ocaliva benefit in transplant-free survival in liver disease type

Intercept cuts debt further with deal to exchange convertible notes

Intercept reduces debt with repurchases of $327.9M convertible notes

Intercept Pharmaceuticals: Too Risky To Buy At This Stage

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Intercept Pharma Q2 2022 Earnings Preview

Intercept Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Consensus forecasts updated

Forecast breakeven date moved forward to 2022

Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)

Intercept to resubmit for FDA approval of NASH candidate after new analysis

Intercept Pharmaceuticals, Inc. Provides Update on Nash Regulatory Timeline

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Intercept: Increase Of Ocaliva Sales And A Few Catalysts

Consensus estimates of losses per share improve by 93%

Forecast breakeven date moved forward to 2022

Intercept Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis

Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

Forecast breakeven date moved forward to 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Intercept Pharmaceuticals, Inc., Annual General Meeting, May 25, 2022

Consensus estimates of losses per share improve by 29%

Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH

Full year 2021 earnings: EPS exceeds analyst expectations

Intercept Pharmaceuticals, Inc. Provides Sales Guidance for the Fiscal Year 2022